Related Experiment Video

Updated: Jul 24, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Ruihong Dong1,2, Ting Ding1,2, Zhengyu Li1,2

  • 1Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China.

Frontiers in Pharmacology
|July 10, 2023
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors are crucial for treating ovarian cancer but face resistance. This review explores resistance mechanisms and combination strategies to improve treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer is a prevalent reproductive system tumor with increasing incidence in China.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) target DNA repair enzymes, effective against tumors with homologous recombination dysfunction.
  • PARPi are clinically used for advanced ovarian epithelial cancer maintenance therapy.

Purpose of the Study:

  • To review the mechanisms underlying Poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer.
  • To summarize current advancements in Poly(ADP-ribose) polymerase inhibitor-based combination strategies.

Main Methods:

  • Literature review of studies on Poly(ADP-ribose) polymerase inhibitor resistance.
  • Analysis of research on combination therapies involving Poly(ADP-ribose) polymerase inhibitors.

Main Results:

  • Drug resistance to Poly(ADP-ribose) polymerase inhibitors is a growing clinical challenge.
  • Various intrinsic and acquired resistance mechanisms have been identified.
  • Combination strategies show promise in overcoming resistance.

Conclusions:

  • Understanding Poly(ADP-ribose) polymerase inhibitor resistance mechanisms is critical.
  • Developing novel combination therapies is essential to enhance treatment outcomes for ovarian cancer patients.
Keywords:
combination therapydrug resistancemechanismovarian cancerpoly ADP-ribose polymerase inhibitors

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K